Preliminary data from Phase I-II studies of anti-IL-6 in patients with multiple myeloma, castration-resistant prostate cancer and other solid tumors indicate the possible development of anti-IL-6 in cancer patients [41-43]. The gene discussed is IL6; the disease is plasma cell myeloma.